Bioinformatics Clinical Research Pharmacokinetics 
Drug Target Review
JULY 12, 2023
The clinical-stage oncology company develops medicines for broad populations of cancer patients and aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway, selectively impacting cancer cells while sparing healthy cells.
The Pharma Data
SEPTEMBER 1, 2020
study investigator and Professor of Clinical Neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center. Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod.
Expert insights. Personalized for you.
98 
Let's personalize your content